Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036855 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00036855: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00036855 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036855, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver radioactive tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by anticancer therapy
Interventions
- BIOLOGICAL rituximab
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- RADIATION yttrium Y 90 ibritumomab tiuxetan
- RADIATION indium In 111 ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036855
The ClinicalTrials.gov registry entry for NCT00036855 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00036855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036855 about?
NCT00036855 is a clinical study titled "Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma". Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver radioactive tumor-killing s...
What is the current status of trial NCT00036855?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2002-06.
What interventions are being tested in trial NCT00036855?
The interventions under investigation include: rituximab (BIOLOGICAL), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), yttrium Y 90 ibritumomab tiuxetan (RADIATION), indium In 111 ibritumomab tiuxetan (RADIATION).
Who is sponsoring clinical trial NCT00036855?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.